Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6.
Systemic sclerosis (SSc), also known as scleroderma, is a complex, multisystem disease that results in severe morbidity, disability, and life-threatening complications. The wide range of biological systems clinically involved, and the large spectrum of disease activity and damage that occurs in this disease have limited clinical investigation of SSc, especially therapeutic trials. The OMERACT 6 Workshop on Systemic Sclerosis was conceived as a starting point for the process of assessing the current state of the science in outcome assessment in SSc and then setting a realistic research agenda and priorities for future work in this area This article reviews the current status of assessment tools for research in SSc within the main fundamental domains of illness in SSc, including problems related to skin, pulmonary, cardiac, peripheral vascular (Raynaud's phenomenon and digital ulceration), renal, and musculoskeletal systems as well as health-related quality of life and physical functioning. The current level of validation of outcome measures in SSc is assessed according to the guidelines set forth by prior OMERACT meetings.
Merkel
Peter A
PA
Arthritis Center, Section of Rheumatology, Boston University School of Medicine, Boston, MA 02118, USA. pmerkel@bu.edu
Clements
Philip J
PJ
Reveille
John D
JD
Suarez-Almazor
Maria E
ME
Valentini
Gabriele
G
Furst
Daniel E
DE
D002986:Clinical Trials as Topic / Q000592:standards*; D006305:Health Status Indicators; D006801:Humans; D015203:Reproducibility of Results; D012595:Scleroderma, Systemic / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D016896:Treatment Outcome